
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9136788/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility. Rheumatology International, 2021, , 1.	3.0	1
2	Fatal Thrombotic Microangiopathy and Posterior Reversible Encephalopathy Syndrome in a Patient with anti-Melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis. Internal Medicine, 2021, 60, 3329-3333.	0.7	3
3	A novel multi-biomarker combination predicting relapse from long-term remission after discontinuation of biological drugs in rheumatoid arthritis. Scientific Reports, 2021, 11, 20771.	3.3	6
4	A Non-smoking Woman with Anti-phospholipid Antibodies Proved to Have Thromboangiitis Obliterans. Internal Medicine, 2020, 59, 439-443.	0.7	3
5	Unilateral bamboo node of the vocal fold associated with anti-SS-A and anti-SS-B antibody. Auris Nasus Larynx, 2020, 47, 706-710.	1.2	4
6	Risk factors correlated with immunosuppressant discontinuation in antineutrophil cytoplasmic antibodyâ€associated vasculitis patients. International Journal of Rheumatic Diseases, 2020, 23, 1587-1593.	1.9	1
7	Increase of a wide range of bioactive substances in an active phase of neuro-Sweet disease. BMJ Case Reports, 2020, 13, e233457.	0.5	1
8	<i>Salmonella enterica</i> Subspecies <i>arizonae</i> Detected from Bilateral Pleural Fluid in a Patient with Systemic Lupus Erythematosus and Malignant Lymphoma. Internal Medicine, 2020, 59, 1223-1226.	0.7	2
9	Series: Diagnosis at a Glance. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 835-837.	0.0	0
10	Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?. Archives of Osteoporosis, 2019, 14, 84.	2.4	3
11	Arteriovenous fistula-related renal bleeding 5Âdays after percutaneous renal biopsy. CEN Case Reports, 2019, 8, 280-284.	0.9	3
12	Simultaneous Oculomotor and Facial Nerve Palsies in a Patient with Systemic Lupus Erythematosus and Sjögren's Syndrome. Case Reports in Rheumatology, 2019, 2019, 1-3.	0.6	2
13	Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatology International, 2019, 39, 901-909.	3.0	16
14	Ruptured Baker's Cyst in Rheumatoid Arthritis. Internal Medicine, 2019, 58, 455-455.	0.7	4
15	Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still's disease: A multicenter retrospective study. Modern Rheumatology, 2018, 28, 858-864.	1.8	21
16	Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan― Rheumatology International, 2018, 38, 663-668.	3.0	15
17	Independent association of HLA-DPB1*02:01 with rheumatoid arthritis in Japanese populations. PLoS ONE, 2018, 13, e0204459.	2.5	6
18	<i>Raoultella planticola</i> Bacteremia in a Patient with Early Gastric Cancer. Internal Medicine, 2018, 57, 1469-1473.	0.7	4

Seiji Μίνοτα

#	Article	IF	CITATIONS
19	Adeno-associated Virus Vector-mediated Interleukin-10 Induction Prevents Vascular Inflammation in a Murine Model of Kawasaki Disease. Scientific Reports, 2018, 8, 7601.	3.3	19
20	Series: Diagnosis at a Glance. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 133-135.	0.0	0
21	Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Modern Rheumatology, 2017, 27, 95-101.	1.8	16
22	Unaffected reaction level in tuberculin skin test by longâ€ŧerm therapy with tumor necrosis factor inhibitors for rheumatoid arthritis. International Journal of Rheumatic Diseases, 2017, 20, 584-588.	1.9	2
23	Extensive Ecchymosis due to Rotator Cuff Tear. Journal of Rheumatology, 2017, 44, 1875-1875.	2.0	Ο
24	Gottron Sign with Ulceration Is Not a Poor Prognostic Factor in Patients with Dermatomyositis and Interstitial Lung Disease. Journal of Rheumatology, 2017, 44, 1099-1100.	2.0	5
25	Comment on: retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. International Journal of Rheumatic Diseases, 2017, 20, 2211-2213.	1.9	2
26	Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate–polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis. Modern Rheumatology, 2017, 27, 411-416.	1.8	13
27	Multicentric Reticulohistiocytosis with Dermatomyositis-like Eruptions. Internal Medicine, 2017, 56, 2063-2066.	0.7	3
28	Deep Cutaneous Ulcers in Dermatomyositis. Internal Medicine, 2017, 56, 1749-1750.	0.7	3
29	A Clinicopathologic Study of Small Intestinal Perforations in Patients With Eosinophilic Granulomatosis With Polyangiitis: A Series of 3 Patients. International Surgery, 2017, 102, 210-215.	0.1	Ο
30	Umbilical Plaque in Psoriatic Arthritis. Internal Medicine, 2017, 56, 235-236.	0.7	0
31	Series: Diagnosis at a Glance. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1489-1490.	0.0	Ο
32	Clinical and Genetic Features of Patients With <i>TNFRSF1A</i> Variants in Japan: Findings of a Nationwide Survey. Arthritis and Rheumatology, 2016, 68, 2760-2771.	5.6	21
33	Intraorbital Granuloma in Granulomatosis with Polyangiitis. Internal Medicine, 2016, 55, 1403-1403.	0.7	0
34	Autoimmune Hemolytic Anemia Induced by Adalimumab. Internal Medicine, 2016, 55, 715-715.	0.7	1
35	A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab. Modern Rheumatology, 2016, 26, 813-816.	1.8	13
36	A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 12.	3.5	30

#	Article	IF	CITATIONS
37	Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. International Journal of Rheumatic Diseases, 2016, 19, 470-475.	1.9	66
38	Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Annals of the Rheumatic Diseases, 2016, 75, 1654-1660.	0.9	89
39	Comment on "Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis―by Yokoyama et al Modern Rheumatology, 2016, 26, 635-635.	1.8	1
40	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 1354-1362.	3.4	26
41	Hypertrophic Osteoarthropathy Associated with Esophageal Cancer. Internal Medicine, 2015, 54, 357-358.	0.7	4
42	Arthritis Mutilans in a Patient with Juvenile Idiopathic Arthritis. Internal Medicine, 2015, 54, 689-689.	0.7	1
43	Pseudorheumatoid Arthritis Caused by Calcium Pyrophosphate Dihydrate Deposition. Internal Medicine, 2015, 54, 2957-2957.	0.7	0
44	Case of H syndrome with massive skin involvement, retroperitoneal fibrosis and Raynaud's phenomenon with a novel mutation in theSLC29A3gene. Journal of Dermatology, 2015, 42, 1169-1171.	1.2	11
45	Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis. Case Reports in Rheumatology, 2015, 2015, 1-4.	0.6	0
46	Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology, 2015, 54, 1128-1129.	1.9	2
47	No increase in synovial fluid level of matrix metalloproteinase-3 by systemic administration of glucocorticoids in rheumatoid arthritis. European Journal of Internal Medicine, 2015, 26, 371-372.	2.2	2
48	Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company. Modern Rheumatology, 2015, 25, 493-494.	1.8	1
49	Successful treatment of a patient with SAPHO syndrome with certolizumab pegol. Rheumatology International, 2015, 35, 1607-1608.	3.0	11
50	Gross hematuria caused by the nutcracker syndrome. Clinical and Experimental Nephrology, 2015, 19, 982-983.	1.6	0
51	Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab. Journal of Rheumatology, 2015, 42, 712-722.	2.0	90
52	Invasive sphenoid sinus aspergillosis mimicking giant cell arteritis. International Journal of Rheumatic Diseases, 2014, 17, 476-478.	1.9	5
53	Caution is needed when interpreting changes of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Rheumatology International, 2014, 34, 1025-1026.	3.0	0
54	Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon. Rheumatology International, 2014, 34, 1623-1626.	3.0	9

#	Article	IF	CITATIONS
55	MRI of Spinal Ligament Enthesitis in a Patient with Spondyloarthritis. Internal Medicine, 2014, 53, 2657-2658.	0.7	1
56	Pseudogout of the Sternoclavicular Joints. Internal Medicine, 2014, 53, 521-522.	0.7	5
57	Posterior ischemic optic neuropathy in a patient with granulomatosis with polyangiitis (Wegener's). Rheumatology International, 2013, 33, 1915-1916.	3.0	6
58	An unusual cause of hemichorea-hemiballism in a patient with systemic lupus erythematosus. Rheumatology International, 2013, 33, 267-268.	3.0	1
59	lgG anti–NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis and Rheumatism, 2013, 65, 457-463.	6.7	89
60	Physico-chemical characteristics of TNF $\hat{I}\pm$ blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds. Modern Rheumatology, 2013, 23, 1034-1036.	1.8	1
61	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Modern Rheumatology, 2013, 23, 945-952.	1.8	20
62	Radiographic Features of Rhupus Arthropathy. Internal Medicine, 2013, 52, 2837-2837.	0.7	1
63	Glucocorticoid-induced Normotensive Scleroderma Renal Crisis: A Report on Two Cases and a Review of the Literature in Japan. Internal Medicine, 2013, 52, 1833-1837.	0.7	5
64	Physico-chemical characteristics of TNFα blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds. Modern Rheumatology, 2013, 23, 1034-1036.	1.8	0
65	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Modern Rheumatology, 2013, 23, 945-952.	1.8	7
66	Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2012, 22, 532-540.	1.8	24
67	Comment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks―by Yokoe et al Modern Rheumatology, 2012, 22, 638-639.	1.8	1
68	Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Modern Rheumatology, 2012, 22, 727-737.	1.8	43
69	Progressive Multicentric Reticulohistiocytosis. Internal Medicine, 2012, 51, 687-688.	0.7	2
70	Marked Colonic Wall Thickening in Lupus Enteritis. Internal Medicine, 2012, 51, 1451-1451.	0.7	2
71	Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Modern Rheumatology, 2012, 22, 712-719.	1.8	53
72	Foot Ulcers Caused by Rheumatoid Vasculitis in a Patient with Rheumatoid Arthritis Undergoing Etanercept Treatment. Internal Medicine, 2012, 51, 3181-3183.	0.7	4

Seiji Μίνοτα

#	Article	IF	CITATIONS
73	Antiribosomal-P protein antibodies are associated with proliferative glomerulonephritis more strongly than with membranous glomerulonephritis in Japanese patients with systemic lupus erythematosus. Modern Rheumatology, 2012, 22, 488-490.	1.8	3
74	Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatology International, 2012, 32, 3691-3694.	3.0	11
75	Healthcare-associated infections in rheumatology in Japan. Rheumatology International, 2012, 32, 801-804.	3.0	3
76	Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response. Rheumatology International, 2012, 32, 1397-1401.	3.0	39
77	Subclinical Riedel's thyroiditis with hypothyroidism coexisting with Mikulicz's disease. Rheumatology International, 2012, 32, 1851-1852.	3.0	6
78	Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatology International, 2012, 32, 2231-2232.	3.0	19
79	Comment on: Churgâ€6trauss syndrome: a retrospective study of 11 cases from a single center in Japan. International Journal of Rheumatic Diseases, 2012, 15, e2-3.	1.9	0
80	Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2012, 22, 532-540.	1.8	19
81	Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Modern Rheumatology, 2012, 22, 712-719.	1.8	33
82	Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Modern Rheumatology, 2012, 22, 727-737.	1.8	21
83	Antiribosomal-P protein antibodies are associated with proliferative glomerulonephritis more strongly than with membranous glomerulonephritis in Japanese patients with systemic lupus erythematosus. Modern Rheumatology, 2012, 22, 488-490.	1.8	2
84	Comment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12Âweeks―by Yokoe et al Modern Rheumatology, 2012, 22, 638-639.	1.8	0
85	Successful Treatment of a Patient with Rheumatoid Arthritis and IgA-Kappa Multiple Myeloma with Tocilizumab. Internal Medicine, 2011, 50, 639-642.	0.7	22
86	Moderate incidence of prior rheumatoid arthritis in patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2011, 30, 875-876.	2.2	3
87	Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatology International, 2011, 31, 559-560.	3.0	24
88	Successful treatment with very low-dose etanercept in a patient with etanercept-induced liver dysfunction. Rheumatology International, 2011, 31, 561-562.	3.0	6
89	Antisynthetase syndrome associated with long-standing rheumatoid arthritis. Rheumatology International, 2011, 31, 705-706.	3.0	9
90	Resolution of anti-neutrophil cytoplasmic antibody-associated vasculitis after resection of gastric cancer. Modern Rheumatology, 2010, 20, 102-105.	1.8	7

#	Article	IF	CITATIONS
91	Acute acalculous cholecystitis in systemic sclerosis. Rheumatology International, 2010, 30, 1549-1550.	3.0	1
92	Autoimmune hepatitis and adult-onset Still's disease: can they coexist?. Clinical Rheumatology, 2010, 29, 449-450.	2.2	1
93	Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?. Clinical Rheumatology, 2010, 29, 819-820.	2.2	7
94	Abrupt Development of Sarcoidosis with a Prodromal Increase in Plasma Osteopontin in a Patient with Rheumatoid Arthritis During Treatment with Etanercept. Journal of Rheumatology, 2010, 37, 210-211.	2.0	11
95	Simultaneous Pneumatosis Cystoides Intestinalis and Pneumomediastinum in a Patient with Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 2194-2195.	2.0	17
96	Is Chlamydia pneumoniae the causative agent of microscopic polyangiitis?. Nephrology Dialysis Transplantation, 2010, 25, 1725-1726.	0.7	0
97	Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-î±. Modern Rheumatology, 2010, 20, 528-530.	1.8	5
98	Increased Levels of Interleukin 33 in Sera and Synovial Fluid from Patients with Active Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 18-25.	2.0	145
99	Resolution of anti-neutrophil cytoplasmic antibody-associated vasculitis after resection of gastric cancer. Modern Rheumatology, 2010, 20, 102-105.	1.8	6
100	Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α. Modern Rheumatology, 2010, 20, 528-530.	1.8	5
101	Potent Induction of IFN-α and Chemokines by Autoantibodies in the Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus. Journal of Immunology, 2009, 182, 1192-1201.	0.8	131
102	Destructive Arthropathy Associated with Dermatomyositis Sine Myositis Positive for Anti-Jo-1 and Anti-Cyclic Citrullinated Peptide Antibodies. Journal of Rheumatology, 2009, 36, 2133-2134.	2.0	18
103	Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clinical Rheumatology, 2009, 28, 485-487.	2.2	66
104	Protein-losing gastroenteropathy associated with primary Sjögren's syndrome: a characteristic oriental variant. Rheumatology International, 2009, 29, 817-820.	3.0	22
105	Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatology International, 2009, 29, 1327-1330.	3.0	22
106	Dermatomyositis associated with thyroid cancer: a paraneoplastic syndrome?. Rheumatology International, 2009, 29, 1261-1262.	3.0	16
107	Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases. Current Pharmaceutical Design, 2009, 15, 2778-2783.	1.9	20
108	Pyoderma gangrenosum associated withÂTakayasu's arteritis without typical symptoms. European Journal of Dermatology, 2009, 19, 266-267.	0.6	5

#	Article	IF	CITATIONS
109	Polyarthritis induced by nonepisodic angioedema associated with eosinophilia. Rheumatology International, 2008, 28, 1065-1066.	3.0	5
110	Steroid-refractory severe hepatic failure in adult onset Still's disease responding to cyclosporine. Clinical Rheumatology, 2008, 27, 1451-1453.	2.2	18
111	Hyper-IgG4 Syndrome Characterized with Sclerosing Mediastinitis and Abdominal Tumors. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 814-816.	0.0	0
112	Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 936-8.	2.0	34
113	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Modern Rheumatology, 2007, 17, 464-469.	1.8	33
114	Antibodies to bovine serum albumin do not affect the results of enzyme-linked immunosorbent assays for IgG anti-NR2 glutamate receptor antibodies: Reply to the letter by Hirohata et al. Arthritis and Rheumatism, 2007, 56, 2813-2814.	6.7	4
115	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Modern Rheumatology, 2007, 17, 464-469.	1.8	24
116	ANCA in Atheroembolism; Just a Coincidence or Bearing Cause and Effect?. Internal Medicine, 2006, 45, 495-496.	0.7	2
117	Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. International Immunology, 2006, 18, 573-580.	4.0	46
118	CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clinical Immunology, 2006, 120, 247-259.	3.2	139
119	Kimura's Disease Presenting as Steroid-Responsive Thromboangiitis Obliterans. Circulation, 2006, 114, e10-1.	1.6	14
120	Semiquantitative assessment of the intestinal motility in chronic intestinal pseudo-obstruction in systemic sclerosis and mixed connective tissue disease by Sitzmarks capsule. Modern Rheumatology, 2006, 16, 330-331.	1.8	1
121	Semiquantitative assessment of the intestinal motility in chronic intestinal pseudo-obstruction in systemic sclerosis and mixed connective tissue disease by Sitzmarks capsule. Modern Rheumatology, 2006, 16, 330-331.	1.8	0
122	Marked pneumatosis cystoides intestinalis in a patient with mixed connective tissue disease. Journal of Rheumatology, 2006, 33, 1705-6.	2.0	7
123	Rapidly aggravated <i>Mycobacterium avium</i> infection in a patient with rheumatoid arthritis treated with infliximab. Modern Rheumatology, 2005, 15, 62-64.	1.8	22
124	Sjoegren's Syndrome Associated with Chronic Hepatitis C, Severe Thrombocytopenia, Hypertrophic Cardiomyopathy, and Diabetes Mellitus. Internal Medicine, 2005, 44, 657-661.	0.7	6
125	Kikuchi?s disease involving the supraclavicular lymph nodes and associated with transient eruption. Rheumatology International, 2005, 25, 143-145.	3.0	3
126	Muscular polyarteritis nodosa as a cause of fever of undetermined origin: a case report and review of the literature. Rheumatology International, 2005, 25, 394-397.	3.0	37

Seiji Μίνοτα

#	Article	IF	CITATIONS
127	Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Modern Rheumatology, 2005, 15, 62-64.	1.8	16
128	Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. Journal of Rheumatology, 2005, 32, 34-9.	2.0	76
129	Marked dilatation of pulmonary arteries in mixed connective tissue disease. Journal of Rheumatology, 2005, 32, 1168-9.	2.0	Ο
130	Nocardia arthritidis sp. nov., a New Pathogen Isolated from a Patient with Rheumatoid Arthritis in Japan. Journal of Clinical Microbiology, 2004, 42, 2366-2371.	3.9	54
131	Rheumatoid Arthritis Complicated with Acute Interstitial Pneumonia Induced by Leflunomide as an Adverse Reaction. Internal Medicine, 2004, 43, 1201-1204.	0.7	94
132	Acute Gout Attack in the Wrist Joint. Internal Medicine, 2004, 43, 641-642.	0.7	3
133	Rapidly Progressed Secondary Amyloidosis in a Patient with Mixed Connective Tissue Disease. Internal Medicine, 2004, 43, 878-882.	0.7	3
134	Prevalence of HSP47 antigen and autoantibodies to HSP47 in the sera of patients with mixed connective tissue disease. Biochemical and Biophysical Research Communications, 2003, 303, 413-418.	2.1	44
135	Acute Immune Thrombocytopenic Purpura in a 90-year-old Woman Treated with Immunoglobulin as well as Clucocorticoid. Internal Medicine, 2003, 42, 1265-1266.	0.7	0
136	A Novel Costimulation Pathway Via the 4C8 Antigen for the Induction of CD4+ Regulatory T Cells. Journal of Immunology, 2002, 169, 3710-3716.	0.8	28
137	von Recklinghausen Disease in a Patient with X-linked Agammaglobulinemia Internal Medicine, 2002, 41, 1039-1043.	0.7	9
138	Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis and Rheumatism, 2002, 46, 3388-3389.	6.7	118
139	Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. Journal of Rheumatology, 2002, 29, 707-16.	2.0	102
140	Production of thromboxane A2 and prostaglandin i2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis. Journal of Rheumatology, 2002, 29, 2106-13.	2.0	2
141	Elevated muscle enzymes in a patient with severe hypocalcemia mimicking polymyositis. Modern Rheumatology, 2002, 12, 186-189.	1.8	0
142	Interaction between monocytes and vascular endothelial cells induces adrenomedullin production. Atherosclerosis, 2001, 155, 381-387.	0.8	13
143	Identification of Human ST2 Protein in the Sera of Patients with Autoimmune Diseases. Biochemical and Biophysical Research Communications, 2001, 284, 1104-1108.	2.1	124
144	Antineutrophil cytoplasmic autoantibody specific for proteinase 3 in a patient with shunt nephritis induced by Gemella morbillorum. American Journal of Kidney Diseases, 2001, 37, e38.1-e38.4.	1.9	14

#	Article	IF	CITATIONS
145	Lipophilic Statins Augment Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Cardiac Myocytes. Journal of Cardiovascular Pharmacology, 2001, 38, 69-77.	1.9	53
146	Gene Transfer into Rat Renal Cells Using Adeno-Associated Virus Vectors. American Journal of Nephrology, 2000, 20, 242-247.	3.1	8
147	Fluvastatin Upregulates Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Vascular Smooth Muscle Cells. Hypertension, 2000, 36, 923-928.	2.7	46
148	Nucleolin as the Earliest Target Molecule of Autoantibodies Produced in MRL/lpr Lupus-Prone Mice. Clinical Immunology, 2000, 97, 50-58.	3.2	23
149	Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune diseases: comparison with antibodies against other Hsp60 family proteins. Cell Stress and Chaperones, 2000, 5, 337.	2.9	59
150	Characterization of the 4C8 Antigen Involved in Transendothelial Migration of CD26hi T Cells after Tight Adhesion to Human Umbilical Vein Endothelial Cell Monolayers. Journal of Experimental Medicine, 1999, 189, 979-990.	8.5	44
151	Homocysteine Increases Nitric Oxide Synthesis in Cytokine-Stimulated Vascular Smooth Muscle Cells. Circulation, 1999, 99, 1230-1235.	1.6	62
152	Preferential Binding withEscherichia colihsp60 of Antibodies Prevalent in Sera from Patients with Rheumatoid Arthritis. Clinical Immunology and Immunopathology, 1997, 82, 141-148.	2.0	16
153	Correlation of serum IgG antibodies to recombinant PO fusion protein with IgG antibodies to carboxylterminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-deleted recombinant PO fusion protein in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1997, 40, 1364-1365.	6.7	10
154	Regulation of ICAM-1 expression by inflammatory cytokines in rat mesangial cells. Cytokine, 1996, 8, 109-114.	3.2	10
155	Histiocytic Cytophagic Panniculitis which Developed during InterferonALPHA. Therapy Internal Medicine, 1996, 35, 115-118.	0.7	11
156	Selective Accumulation of Anti-histone Antibodies in Glomeruli of Lupus-ProneIprMice. Clinical Immunology and Immunopathology, 1996, 80, 82-87.	2.0	19
157	Rabbit anti-chromatin antibodies recognize similar epitopes on a histone H1 molecule as lupus autoantibodies. Clinical Immunology and Immunopathology, 1995, 77, 52-58.	2.0	12
158	Interrelationship between Autoepitope, DNA-Binding Domain, and CRP-Binding Domain on a Histone H1 Molecule. Clinical Immunology and Immunopathology, 1993, 66, 269-271.	2.0	14
159	Autoantibodies to nucleolin cross-react with histone H1 in systemic Lupus erythematosus. Molecular Biology Reports, 1992, 16, 263-266.	2.3	10
160	Correlative expression of C3b receptors in the glomerulus and on erythrocytes. Clinical Immunology and Immunopathology, 1986, 38, 85-92.	2.0	0
161	Low capacity of erythrocytes to bind with immune complexes via C3b receptor in patients with systemic lupus erythematosus: Correlation with pathological proteinuria. Clinical Immunology and Immunopathology, 1985, 34, 109-117.	2.0	14
162	Relationship of anti-β2-microglobulin antibodies to T11 and T-cell activation in systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1985, 37, 179-190.	2.0	5